Abstract 344P
Background
Acute myeloid leukemia (AML) is primarily treated with chemotherapy. Patients who are unable to undergo intensive chemotherapy may receive substitutional therapy, such as venetoclax, a BCL-2 inhibitor that showed promising results by combining it with azacitidine. Recent clinical trials have demonstrated the effectiveness of venetoclax-azacitidine in AML treatment. Thus, this review aims to compare the efficacy and serious adverse events (SAE) of venetoclax-azacitidine vs azacitidine used alone in patients diagnosed with AML.
Methods
Authors independently extracted studies from 2013 to 2023 using databases such as Pubmed, Pubmed Central, Springer Link, ScienceDirect, Medrxiv, and Google Scholar. Keywords used were "venetoclax" AND "azacitidine" AND "acute myeloid leukemia". We assessed the quality of each study using the modified JADAD scale with funnel plot to assess publication bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) to determine the quality of this review. A pooled analysis of OS and EFS hazard ratio (HR) and SAE ratio between the two groups were done to establish correlation.
Results
We included 7 records, representing 3 trials, involving 1499 patients. 2 studies were of low quality, with the other 3 studies and the other 2 studies were of moderate and high quality respectively. This review showed moderate quality based on GRADE with minimum publication bias. The use of combining venetoclax and azacitidine did improve OS (HR = 0.58; 95% CI 0.51-0.65 ; P < 0.001) and EFS (HR = 0.50 ; 95% CI 0.30-0.84 ; P = 0.008), but have higher SAE (OR = 1.81 ; 95% CI 1.29-2.52 ; P = 0.0005) compared to azacitidine alone.
Conclusions
This review revealed that venetoclax-azacitidine demonstrated enhanced OS and EFS outcomes, with higher serious adverse events (SAE) when compared to azacitidine in AML patients. This concludes that venetoclax-azacitidine holds promise as a potential treatment for AML patients although its safety still needs to be monitored closely. Further studies needed to observe the administration of venetoclax-azacitidine vs azacitidine AML in different subgroups, more importantly the cytogenetic risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract